key: cord-0805704-03ime8qf
authors: Tang, Yueting; Sun, Jiayu; Pan, Huaqin; Yao, Fen; Yuan, Yumeng; Zeng, Mi; Ye, Guangming; Yang, Gui; Zheng, Bokun; Fan, Junli; Pan, Yunbao; Zhao, Ziwu; Guo, Shuang; Liu, Yinjuan; Liao, Fanlu; Duan, Yongwei; Jiao, Xiaoyang; Li, Yirong
title: Aberrant Cytokine Expression in COVID-19 Patients: Associations between Cytokines and Disease Severity
date: 2021-03-31
journal: Cytokine
DOI: 10.1016/j.cyto.2021.155523
sha: b4010e84bf71d1d160b3cd80d7dddf8510b378de
doc_id: 805704
cord_uid: 03ime8qf

Cytokines play pleiotropic, antagonistic, and collaborative in viral disease. The high morbidity and mortality of coronavirus disease 2019 (COVID-19) make it a significant threat to global public health. Elucidating its pathogenesis is essential to finding effective therapy. A retrospective study was conducted on 71 patients hospitalized with COVID-19. Data on cytokines, T lymphocytes, and other clinical and laboratory characteristics were collected from patients with variable disease severity. The effects of cytokines on the overall survival (OS) and event-free survival (EFS) of patients were analyzed. The critically severe and severe patients had higher infection indexes and significant multiple organ function abnormalities than the mild patients (P<0.05). IL-6 and IL-10 were significantly higher in the critically severe patients than in the severe and mild patients (P<0.05). IL-6 and IL-10 were closely associated with white blood cells, neutrophils, T lymphocyte subsets, D-D dimer, blood urea nitrogen, complement C1q, procalcitonin C-reactive protein. Moreover, the IL-6 and IL-10 levels were closely correlated to dyspnea and dizziness (P<0.05). The patients with higher IL-10 levels had shorter OS than the group with lower levels (P<0.05). The older patients with higher levels of single IL-6 or IL-10 tended to have shorter EFS (P<0.05), while the patients who had more elevated IL-6 and IL-10 had shorter OS (P<0.05). The Cox proportional hazard model revealed that IL-6 was the independent factor affecting EFS. IL-6 and IL-10 play crucial roles in COVID-19 prognosis.

The high morbidity and mortality of COVID-19 make it a significant threat to global public health. The latest data reported more than one hundred million laboratory-confirmed cases with over two million deaths worldwide. Internationally, cases have been reported in over 200 countries and five continents [1] . The SARS-CoV-2 predominantly infects the lower respiratory tract and intestinal tract, presenting fever, non-productive cough, dyspnea, myalgia, fatigue, normal or decreased lymphocyte counts, and radiographic evidence pneumonia at diagnosis. Organ dysfunction (for example, shock, acute respiratory distress syndrome [ARDS], acute cardiac injury, and acute kidney injury), and death frequently occur in severe cases [2] .

The patients were divided into four types according to disease severity: no symptoms, mild/moderate, severe, and critically severe. The disease severity was influenced by the initial viral titers, age, and comorbid conditions of the infected individual. Older age is generally considered an essential element in disease severity. In Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS), younger individuals experience mild to moderate clinical illness, while elderly individuals exhibit worse outcomes after infection [3] [4] [5] . In COVID-19, similar median patient age was reported in different clinical cohorts [2, 6] ; however, severe or critically severe COVID-19 was also observed in young people, and some young individuals experienced dramatic disease deterioration, even in cases that had previously demonstrated few comorbidities. Though the factors causing COVID-19's unusually high morbidity and mortality remain incompletely understood, mechanisms like thromboembolic risk have been learned over the past several months. Clotting factors like factor V [7, 8] , thrombin-antithrombin complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), thrombomodulin (TM), t-PA/PAI-1 Complex (t-PAIC) and other coagulation parameters [9] , links to venous thromboembolism and mortality risk, and nominate a candidate biomarker to investigate for guiding anticoagulation therapy COVID-19. More importantly, a few recent studies revealed that cytokine storm (inflammatory cytokines, such as TNF-α, IL-1β, VEGF and IL- 6) could increase microvascular permeability and induce intravascular coagulation with embolization of different organs in COVID-19 [10] [11] [12] .

The complex interplay between the host antiviral immune responses and the viral ability to modify these responses are critical for disease severity. Previous studies elucidated a pivotal role for virus-associated immunopathological events in causing fatal pneumonia in MERS and SARS patients that are often associated with massive inflammatory cell infiltration and elevated proinflammatory cytokine responses called hypercytokinemia in patients [13] . Cytokine storms are an important underlying cause of mortality in patients infected with severe emerging viruses, including Ebola, Marburg, MERS-CoV, pandemic influenza, and others [14] . SARS patients with worse outcomes had high levels of proinflammatory cytokines [15, 16] , indicating that immune response-associated lung immunopathology might determine the outcome of infected patients. The effects of cytokine storms coupled with acute viral infection in the host can be complicated, overwhelming, and potentially fatal.

This raised a question about the role of cytokine storms in the pathogenesis of In this study, we demonstrate the change in cytokines and T lymphocytes together with the clinical symptoms and laboratory parameters of COVID-19 patients with different disease status. Our results may explain the pathogenesis of COVID-19.

The Ethics committee of Zhongnan Hospital of Wuhan University approved the study ( pneumonia. The severe type (meeting any of the following criteria) included respiratory distress, RR more than 30 times/min, finger oxygen saturation less than 93% at rest, and partial arterial oxygen pressure (PaO2)/oxygen absorption (FiO2) concentration less than or equal to 300 mmHg. The critically severe type included respiratory failure requiring mechanical ventilation, shock, and a combination of other organ failures requiring treatment in the intensive care unit. The patients' medical records, including clinical data, laboratory results, radiological characteristics, treatments, and outcome data, were obtained with data collection forms from the electronic medical records at Zhongnan Hospital [6] .

The serum cytokines, including IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, and IFN-γ, were measured using BD FACSCalibur flow cytometry. The protocol was followed according to the cytometric bead array (CBA) reagent manufacturer's instructions (Node Company, Jiangxi, China).

A total of 2 ml of blood was collected and anticoagulated using heparin sodium or EDTA-k2. Human peripheral blood lymphocyte differentiation antigens (CD) CD3, CD4, CD8, CD19, CD16, and CD56 were detected using flow cytometry according to the manufacturer's instructions (Becton, Dickinson and Company, BD Biosciences, San Jose, CA, USA).

Throat swab samples were collected to extract SARS-CoV-2 RNA. from the suspected patients. The real-time RT-PCR assay was conducted using a SARS-CoV-2 nucleic acid detection kit according to the manufacturer's protocol (Shanghai Biogerm Medical Technology, Co. Ltd.). A cycle threshold value (Ct value) less than 37 was defined as a positive test result, and a Ct value of 40 or more was identified as a negative test.

(http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html).

Data are presented as mean ± standard deviation (SEM 

Compared to the mild patients, the critically severe patients had significantly higher (P<0.05) ( Table 2 ). Our data showed that the critically severe patients had liver/renal function abnormalities, abnormal myocardial zymograms, and high infection indexes (P<0.05). Comparing the critically severe and severe patients, WBC, NEUT, PT, HSTNI, and PCT was significantly higher, while CO 2 was markedly lower in the critically severe group than in the severe group (P<0.05). There were significantly higher levels of GLU, ALT, CK-MB, and CRP and lower levels of lymphocytes, Ca2+, ALB, and TP in the severe group than in the mild group (P<0.05) ( Table 2 ).

The IL-6 concentration in the critically severe group was 19-fold higher than in the mild group and 7-fold higher than in the severe group at disease onset. IL-6 in the severe type was 2.8-fold higher than in the mild group (P<0.05) (Fig. 1a ). The IL-10 level in the critically severe group was 7-fold higher than in the mild group and 3.7-fold higher than in the severe group. IL-10 in the severe group was 1.9-fold higher than in the mild group (P<0.05) (Fig. 1b) . There was no significant difference in IL-2, IL-4, TNF-α, and IFN-γ among the three groups (P>0.05) (Fig. 1 ).

A longitudinal analysis of the progressive changes in IL-6 was conducted in the critically severe patients. The fluctuating changes chart typically showed one single peak of IL-6 in 8 patients (Fig. 2a) . Specific treatments also influenced the IL-6 level. For example, patient No. 9 received plasma (from convalescent COVID-19 patients) infusion 25 days after disease onset, and their IL-6 level decreased significantly to the normal range over the following two days. Patient No. 12 demonstrated a slight decrease in IL-6 in the up-slope phase from days 9 to 24 following remdesivir treatment (Fig. 2a) . No particular trend was found in IL-10 ( Fig. 2b) .

There was no significant difference in the percentage of T lymphocyte (CD3+%), helper/inducible T lymphocyte (CD3+CD4+%), and NK. cell (CD16+CD56+%) among the three groups (P>0.05), but the percentage of inhibitory/cytotoxic T lymphocyte (CD3+CD8+%) in the critically severe group was significantly lower than in the mild group (P<0.05) (Fig. 3a) . Patients in the critically severe group also showed a marked decrease in CD3+lymphocyte (Lym) and inhibitory/cytotoxic T lymphocyte (CD3+CD8+Lym) absolute count (Abs) in comparison with the mild group (P<0.05). Conversely, the percentage of B lymphocyte (CD19+%) in the critically severe group was significantly higher than in the severe and mild groups (P<0.05). NK cell absolute count (CD16+CD56+Lym Abs) in the mild group was considerably higher than in the critically severe group (P<0.05) (Fig. 3b ). Table 3) .

IFN-γ levels were closely associated with TNF-α (r=0. 46 Table 3) .

In the critically severe group, ten patients died, eight remained in the ICU, and five improved; three were discharged (out of the total of all critically severe patients and not include in the improved group). In the severe group, eight patients improved, and seven were discharged. In the mild group, 18 improved, and 12 were discharged ( (Fig. 4c) . The other parameters played no significant role in the patients' OS ( (Fig. 4f) . The other parameters played no significant role in the patients' EFS ( 

Due to COVID-19's high mortality, clarifying the risk factors is urgently necessary to develop treatment strategies. WBCs, procalcitonin (PCT), and CRP, markers reflecting the severity of infection [17] , were significantly higher in our critically severe patients than in the mild/moderate group. Lymphocytopenia is a unique feature of COVID-19, and low lymphocytes are suggested to be a reference index in the diagnosis [18] . T cells, particularly CD3+CD8+cells, play a crucial role by combating pathogens and balancing the risk of developing autoimmunity or overwhelming inflammation [19] . In this study, a substantial decrease in the total number of T lymphocytes and CD3+CD8+ cells was observed in the severe patients,

indicating that Coronavirus consumes many immune cells and inhibits the body's cellular immune function. In SARS, decreased T cells' numbers are strongly correlated with the acute disease phase [20, 21] . The consequences of low T lymphocytes and CD3+CD8+ cells in COVID-19 are not completely clear; depletion of T cells with antiviral effects may prolong the disease and promote viral survival [22] , leading to patient exacerbations [23] . Thus, CD3+ and CD3+CD8+ T cell Abs could be considered a parameter that reflects the disease severity of COVID-19.

ARDS is associated with the induction of inflammatory cytokines, including IL-1, IL-6, IL-8, CXCL-10, and TNF-α, many of which are highly expressed in the lungs of patients [24, 25] . A high ARDS ratio was found in our COVID-19 patients, especially in the critically severe group. Therefore, elucidating the role of cytokine expression in disease severity is essential. A notable feature of SARS and MERS is that high viral replication leads to higher levels of proinflammatory cytokine production by infected epithelial cells [26, 27] . Although they may be part of a necessary initial immune response to pathogens, exacerbated expression of proinflammatory cytokines and chemokines is associated with immunopathology and ARDS [28] . In our study, too high levels of IL-6 were observed in the critically severe COVID-19 patients compared to those with mild illness. IL-6 is a major player in integrated immunity via its defense against viral infections [29] . However, in some respiratory viral infections, such as influenza and respiratory syncytial virus, elevated IL-6 has been associated with increased lung damage and worse outcomes [29, 30] . In children with pneumonia, IL-6 was correlated with disease severity [31] [32] [33] [34] . In addition to proinflammatory and anti-inflammatory functions, IL-6 enhances mucus production in the airways following allergen exposure [35] . IL-6 can directly induce

Muc5AC and Muc5B mucin gene expression in human lung epithelial cell lines in vitro, and there is a possibility that IL-6 may directly affect mucus production by lung epithelial cells during allergic airway inflammation [36] . A positive correlation between IL-6 and dyspnea was observed in childhood pneumonia, and IL-6 was the only cytokine associated with disease severity [33, 37] . The latest autopsies showed that much mucus accumulated in the pulmonary alveoli and lungs of COVID-19

patients. Excessive mucus production can lead to physical obstruction of smaller caliber airways [38] . A large amount of mucus accumulation in the airways may be the leading cause of dyspnea and respiratory distress in most COVID-19 patients.

Significantly higher levels of IL-6 were present in the critically severe patients, together with a correlation between IL-6 levels and dyspnea, supporting our hypothesis that IL-6 may contribute to mucus production in the lungs and lead to dyspnea. Elucidating the role of IL-6 in COVID-19 pathogenesis will be beneficial for therapy.

In addition to IL-6, high levels of IL-10 were also observed in the critically severe patients. The overall effects of IL-10 on antiviral immune reactions can be complicated and depend on the virus, infection site, antiviral immune response timing, and other factors. High IL-10 could be protective in early reactions to the virus but become detrimental during acute infection as they promote illness persistence [39] . In this study, a close relationship existed between Il-10 and IL-6, and the patients with both high IL-6 and IL-10 were more likely to have dyspnea and ARDS and shorter OS and EFS, indicating that both cytokines may play a synergistic role in COVID-19 pathogenesis. Our results suggested that IL-6 and IL-10 were valuable parameters for evaluating disease prognosis.

Interferons are potent cytokines of critical importance in controlling viral infections and priming adaptive immune responses [40] . Contrary to the higher levels of IL-6 that existed in the critically severe patients, the IFN-γ level was lower in the critically severe patients than in the mild group. Although IL-6 is a negative regulator of IFN-γ [41] , we did not find correlations between IFN-γ and IL-6. The mechanism of lower IFN-γ in severe disease remains to be elucidated. In viral infections, antiviral IFN acts not only to control viral infections but also to program the adaptive immune response to promote viral clearance [42] . CoV reaches high titers very early after [43] .

Despite numerous reports describing the elevation of inflammatory cytokines in primary CoV-infected patients [44] , it is unknown if these cytokines are beneficial or contribute to the pathogenicity of infection. Our evidence from patients with critically severe disease suggests the role of cytokine storms in COVID-19. IL-6 and IL-10 may be involved in organ abnormalities and closely related to disease severity.

Previous studies revealed that immunomodulation is an essential element in treating severe SARS-CoV diseases and avian influenza viral infections [45] [46] [47] .

Unfortunately, there are few effective antiviral treatments for CoV infections, although many drugs have been tested [48] . As an independent risk factor for disease severity, IL-6 might be a potential target for treatment. Now There is currently no standard therapy to treat cytokine storms [14] . Conversely, how are the effects of the different treatments on cytokines and whether they could be biomarkers to monitor response to treatment. Further studies are needed to confirm this.

Significant higher IL-6 and IL-10 were observed in the critically severe COVID-19

patients than the severe and mild patients, which was closely related to dyspnea, ARDS, shorter OS, and EFS. Our results suggested that cytokines and T lymphocytes play a vital role in disease prognosis. Thus, they could be potential targets for treatment. Further studies are needed to confirm cytokines' interactions in COVID-19.

We thank Xiao-Yue Hong, Qiao Ling Deng, Jin Li, Xiao-Juan Wu, and Xue-Ping Qiu for collecting the samples. We appreciate all of our colleagues fighting on the front lines to diagnose and treat COVID-19. We thank all of the patients involved in the study. 

We declare no competing interests. YRL had full access to all of the data in this study and takes responsibility for the data integrity and the accuracy of the data analysis. YRL and XYJ contributed 21 equally and shared the corresponding authorship. Table 3 Correlation between cytokines and other lab parameters in COVID-9 patients YRL had full access to all of the data in this study and takes responsibility for the data integrity and the accuracy of the data analysis. YRL and XYJ contributed equally and shared the corresponding authorship.

Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak -United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious diseases

Coronavirus as a possible cause of severe acute respiratory syndrome

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism

Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality

The values of coagulation function in COVID-19 patients

COVID-19 Sepsis and Microcirculation Dysfunction

SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation

Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab. Advances in respiratory medicine

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Current and future developments in the treatment of virus-induced hypercytokinemia

Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome

Analysis of serum cytokines in patients with severe acute respiratory syndrome

Biomarkers for community-acquired pneumonia in the emergency department

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it?

Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. The Journal of infectious diseases

Rapid loss of both CD4+ and CD8+ T lymphocyte subsets during the acute phase of severe acute respiratory syndrome

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients

SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Toll-Like Receptor

Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection

Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1

Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology

A question of self-preservation: immunopathology in influenza virus infection

Host Inflammatory Biomarkers of Disease Severity in Pediatric Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Open forum infectious diseases

Assessment of Cytokine and Chemokine Signatures as Potential Biomarkers of Childhood Community-acquired Pneumonia Severity: A Nested Cohort Study in India. The Pediatric infectious disease journal

The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia

Cytokine Concentrations in Plasma from Children with Severe and Non-Severe Community Acquired Pneumonia

IL-6 is required for airway mucus production induced by inhaled fungal allergens

Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop

Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. The European respiratory journal

Airway mucus hypersecretion in asthma: an undervalued pathology?

promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis

Links between innate and adaptive immunity via type I interferon

Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation

Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

SARS Immunity and Vaccination

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5. Emerging microbes & infections

A review of treatment modalities for Middle East Respiratory Syndrome

Liver function: ALT: alanine aminotransferase; AST: aspartate aminotransferase

CREA: creatinine; UA: uric acid; CO2: carbon dioxide; CYSC: cystatin C. Cardiac function: CK: creatine kinase; LDH: lactate dehydrogenase; CKMB: creatine kinase-MB; MYO: myoglobin; HSTNI: hypersensitive troponin I. Inflammatory immune index: C1q: complement C1q; PCT: procalcitonin; CRP: C-reactive protein; GLU: glucose. Highlight: 1. IL-6 and IL-10 play a crucial role in the pathogenesis of COVID-19

Combining IL-6 and IL-10 data may provide valuable

Dynamic monitoring IL-6 and IL-10 in COVID-19 may offer the new ideas for therapeutic strategies

P Value <.05 was considered statistically significant. Data were available for 71 patients. IL-6: interleukin-6; IL-6+IL-10: interleukin-6 and interleukin-10 positive;CD3+ Cnt: absolute T lymphocyte count; CD3+CD8+ Cnt: inhibitory/cytotoxic T lymphocyte absolute count. 

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: